SGIOF - Shionogi inks supply deal with Japanese government for oral COVID drug S-217622

Shionogi (OTCPK:SGIOF) (OTCPK:SGIOY) signed a basic agreement with the Ministry of Health, Labor and Welfare (MHLW) to supply its oral COVID-19 drug S-217622 in Japan. The company said it expects the Japanese government to buy 1M courses of S-217622, following approval of the drug, and will continue to buy a certain number after that. Last month, Shionogi had filed for approval of the drug in Japan. This is the first such contract for a domestically-produced oral therapeutic drug for COVID-19, the company said in a March 25 release.

For further details see:

Shionogi inks supply deal with Japanese government for oral COVID drug S-217622